



Signalife

Clear Data. Trusted Results.

Signalife, Inc.
531 South Main St. ~ Suite 301
Greenville, SC 29601
T 864.233.2300
F 864.233.2100
www.signalife.com
info@signalife.com

PRESS RELEASE

Wednesday April 18, 2007 9:09 am ET

Signalife Develops Proprietary Software for Objective Evaluation of Electrocardiograph Performance

GREENVILLE, S.C., April 18, 2007 -- Signalife, Inc. (Amex: SGN - News) announced development of proprietary software that can provide objective evaluation of electrocardiograph performance, including its Fidelity 100 ECG system.

Presently, the objective evaluation of different ECG recorders is performed by parallel recordings of the device under test and the control device. In the case of differences between the two, it is difficult to determine which device recorded the source signal with higher fidelity. A combination of the Signalife simulator and newly developed proprietary software will allow the objective comparison of different electrocardiograph devices.

Budimir S. Drakulic, Signalife's Chief Technology Officer stated, "We have spent considerable time and effort in the development of a simulator and proprietary measurement software. This technology was used to demonstrate the superiority of our Fidelity 100 recorder against electrocardiograph recorders from leading manufacturers. We intend to report our findings in various upcoming scientific meetings."

Pamela Bunes, Company's CEO concluded, "Since the company's inception, we publicized that our technology improves ECG recordings, especially in ambulatory settings. Our presentation at the ISCE meeting in 2005 focused on an important characteristic of modern electrocardiograph devices that incorporates different filter settings to improve visual appearance of ECG tracings. It seems that the electrocardiology community responded well to our efforts to bring attention to this problem as a recent paper by Dr. Paul Kligfield and Dr. Peter Okin entitled 'Prevalence and Clinical Implications of Improper Filter Settings in routine Electrocardiography' published in the March 1st, 2007 issue of the American Journal of Cardiology indicates that our initiative is gaining support. Signalife commits to provide the best possible solution to clinicians and ultimately patients."

About Signalife, Inc.

Signalife, Inc. engages in the research, development, and marketing of signal-monitoring devices for detecting diseases. It primarily offers patient modules that are used as part of a heart monitor system to acquire, amplify, and process physiological signals associated with a patient's cardiovascular system. Signalife is based in Greenville, South Carolina. For more information visit <http://www.signalife.com>.

Caution Regarding Forward-Looking Statements

Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.

Source: Signalife, Inc.

Contact: Kevin Kading 212-918-4606

###